Lifeward announces approval for ReWalk 7 coverage by a major U.S. health insurer, enhancing access for individuals with spinal cord injuries. Approval for reimbursement by a major insurer comes ...
Lifeward Ltd. reported its financial results for the first quarter of 2025, highlighting a continuing build-up of opportunities for the ReWalk exoskeleton with over 120 qualified leads. The company's ...
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the ...
“Nationally nearly half of all Medicare Advantage enrollees are now eligible for prior authorization and reimbursement for ReWalk 7,” said Mark Grant, CEO of Lifeward. “This prior authorization ...
Clinic days offeredat Shirley Ryan AbilityLab, the #1 ranked rehabilitation hospitalfor 35 consecutive years,with the goal ofacceleratingpersonal ...
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal ...
Lifeward is "resetting its full 2025 guidance under the new management team," now expecting full-year revenue in the range of $24 million to $26 million and a projected non-GAAP net loss between $12 ...
Lifeward Ltd. (NASDAQ:LFWD) stock is trading higher on Thursday after the company announced that its ReWalk 7 received 510(k) clearance from the Food and Drug Administration (FDA). What To Know: The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results